

DAY 1 (Original Recording Date: Wednesday, June 3, 2026)

Focus on Diabetes

Cecilia Low Wang, MD - Standards of Care in Diabetes – Highlights from the ADA Standards and AACE T2D Consensus Algorithm

- ADA Professional Practice Committee. 2. Diagnosis and Classification: Standards of Care in Diabetes - 2026. *Diabetes Care* 2026;49(Suppl. 1):S27-S49.
- Samson SL, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2026. *Endocr Pract* 2026;32:473-518.
- Ndumele CE, et al. *Circ* 2023;148:1606-1635.
- Additional references provided within slide presentation.

Carol Wysham, MD - Diabetes and Metabolic Associated Steatotic Liver Disease (MASLD) - Evaluation and Treatment

- Rinella M et al *Hepatology* 2023; 77:1797- 1835
- Cusi K et al. *Endocrine Practice* 2022; 28:528 - 562
- Kanwal F, et al. *Gastroenterology* 2026 (online ahead of print) DOI: 10.1053/j.gastro.2026.01.047
- Additional references provided within slide presentation.

Cecilia Low Wang, MD - Navigating GLP1-RA and SGLT2i Use in Your Patients with Diabetes and Obesity – Incorporating the ADA, AACE and AHA CKM Perspectives

- Kelin S, et al. Why does obesity cause diabetes? *Cell Metab* 2022;34:11-20.
- Powell-Wiley TM, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation* 143:e984–e1010.
- Ndumele CE, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. *Circ* 2023;148:1606-1635
- Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. *JACC* 2020;75(4):422-434.
- Samson SL, et al. *Endocr Pract* 2026;32:473-518.
- ADA PPC. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. *Diabetes Care* 2026;49(Suppl. 1):S216-S245.
- Park C, et al. *Front Endocrinol* 2025; 10.3389/fendo.2025.1630199.
- Additional references provided within slide presentation.

Carol Wysham, MD - Addressing Obesity in Diabetes: Why Weight? (Holistic Management of Diabetes)

- Rinella M et al *Hepatology* 2023; 77:1797- 1835
- Cusi K et al. *Endocrine Practice* 2022; 28:528 - 562
- Kanwal F, et al. *Gastroenterology* 2026 (online ahead of print) DOI: 10.1053/j.gastro.2026.01.047
- Additional references provided within slide presentation.

Drs. Low Wang & Wysham - Cases in Diabetes

- ADA PPC. *Diabetes Care* 2026;49(Suppl. 1).
- Samson SL, et al. *Endocr Pract* 2026;32:473-518.
- Ndumele CE, et al. *Circ* 2023;148:1606-1635.
- Additional references provided within slide presentation.

DAY 2 (Original Recording Date: Thursday, June 4, 2026)

Focus on Hypertension

Jan Basile, MD - What's New in Outpatient Hypertension: Clinical Pearls from the New Hypertension Guideline

- References provided within slide presentation.

Greg Hundemer, MD - MRAs (Steroidal and Non-Steroidal) and Aldosterone Synthase Inhibitors in Hypertension and Renal Disease

- Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B; BaxHTN Investigators. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. *N Engl J Med*. 2025 Oct 9;393(14):1363-1374. doi: 10.1056/NEJMoa2507109. Epub 2025 Aug 30. PMID: 40888730; PMCID: PMC7618089.
- Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. *N Engl J Med*. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. PMID: 40470996.

- Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. *N Engl J Med*. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. PMID: 34449181.
- Additional references provided within slide presentation.

Brent Egan, MD - Hypertension in Older Women: Illuminating a Bright Spot

- 1. Osude N, Durzao-Arvizu R, Markossian T, Liu K, Michos ED, Rakotz M, Wozniak G, Egan B, Kramer H. Age and sex disparities in hypertension control: The multi-ethnic study of atherosclerosis (MESA). *Am J Prev Cardiol*. 2021;8:100230.
- 2. Chapman N, Ching SM, Konradi AO, Nuyt AM, Khan T, Twumasi-Ankrah B, Cho EJ, Schutte AE, Touyz RM, Steckelings UM, Brewster LM. Arterial hypertension in women: State of the art and knowledge gaps. *Hypertension*. 2023;80:1140-1149.
- 3. Egan BM, Li J, Sutherland SE, Riesser BC, Mattix-Kramer H, Rakotz MK. Height may explain sex differences in systolic blood pressure in older adults. *Hypertension*. 2025;82:1857-1865.
- Additional references provided within slide presentation.

Greg Hundemer, MD - Rethinking Primary Aldosteronism

- Turcu AF, Freeman MW, Bancos I, Ben-Shlomo A, Hamidi O, Hamrahian AH, Huang W, Kirschner LS, Sam R, Mallappa A, Tuyishimire B, Lihn AS, Perl S, Brown MJ; SPARK Investigator Group. Phase 2a Study of Baxdrostat in Primary Aldosteronism. *N Engl J Med*. 2025 Jul 31;393(5):515-518. doi: 10.1056/NEJMc2508629. Epub 2025 Jul 13. PMID: 40658651.
- Hundemer GL, Agharazii M, Madore F, Vaidya A, Brown JM, Leung AA, Kline GA, Larose E, Piché ME, Crean AM, Shaw JLV, Ramsay T, Hametner B, Wassertheurer S, Sood MM, Hiremath S, Ruzicka M, Goupil R. Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study. *Circulation*. 2024 Jan 9;149(2):124-134. doi: 10.1161/CIRCULATIONAHA.123.066389. Epub 2023 Nov 30. PMID: 38031887; PMCID: PMC10841691.
- Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, Mulatero P, Murad MH, Touyz RM, Vaidya A, Williams TA, Yang J, Young WF, Zennaro MC, Brito JP. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2025 Aug 7;110(9):2453-2495. doi: 10.1210/clinem/dgaf284. Erratum in: *J Clin Endocrinol Metab*. 2025 Oct 16;110(11):e3933-e3934. doi: 10.1210/clinem/dgaf472. PMID: 40658480.
- Additional references provided within slide presentation.

Brent Egan, MD - Reframing Goal BP to Align Patients and Providers on the Target

- Egan BM, Li J, Wagner CS. Systolic blood pressure intervention trial (SPRINT) and target systolic blood pressure in future hypertension guidelines. *Hypertension*. 2016;68:318-323.
- Bellows BK, Ruiz-Negrón N, Bibbins-Domingo K, King JB, Pletcher MJ, Moran AE, Fontil V. Clinic-based strategies to reach united states million hearts 2022 blood pressure control goals: A simulation study." *Circulation: Cardiovasc Qual Outcomes*. 2019;12:e005624.
- Barrett RB, Riesser B, Martin B, Sachdev N, Rakotz MK, Sutherland SE, Egan BM. Treatment in the first month after hypertension diagnosis improves blood pressure control. *Hypertension*. 2025;82:1129-1136.
- Additional references provided within slide presentation.

Kelsey Bryant, MD - Cases in Hypertension

- Ishigami J, Charleston J, Miller ER, Matsushita K, Appel LJ, Brady TM. Effects of Cuff Size on the Accuracy of Blood Pressure Readings: The Cuff(SZ) Randomized Crossover Trial. *JAMA Internal Medicine*. 2023;183(10):1061.
- Writing Committee Members*, Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP, Carter J, Cohen JB, Collins KJ, Commodore-Mensah Y, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Hypertension*. 2025;82(10).
- Wang N, Salam A, Pant R, Kumar A, Dhurjati R, Haghdoost F, Vidyasagar K, Kaistha P, Esam H, Gnanenthiran SR, Kanukula R, Whelton PK, Egan B, Schutte AE, Rahimi K, et al. Blood pressure-lowering efficacy of antihypertensive drugs and their combinations: a systematic review and meta-analysis of randomised, double-blind, placebo-controlled trials. *The Lancet*. 2025;406(10506):915-925.
- Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, Mulatero P, Murad MH, Touyz RM, Vaidya A, Williams TA, Yang J, Young WF, Zennaro M-C, Brito JP. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology and Metabolism*. 2025;110(9):2453-2495.
- Parisien-La Salle S, Hundemer GL, Nehs MA, Barletta JA, Vaidya A. Treatment of Primary Aldosteronism. *Hypertension*. 2026;83(5):e26238.
- King JB, An J, Bellows BK, Cohen JB, Commodore-Mensah Y, Ghazi L, Langford AT, Brook RD, on behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Single-Pill Combination Therapy for the Management of Hypertension: A Scientific Statement From the American Heart Association. *Hypertension*. 2025:HYP.0000000000000258.
- King JB, Derington CG, Herrick JS, Jacobs JA, Zheutlin AR, Conroy MB, Cushman WC, Bress AP. Single-Pill Combination Product Availability of the Antihypertensive Regimens Used for Intensive Systolic Blood Pressure Treatment in the Systolic Blood Pressure Intervention Trial. *Hypertension*. 2023;80(8):1749-1758.
- Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, Palaniappan LP, Sperling LS, Virani SS, Ho JE, Neeland IJ, Tuttle KR, Rajgopal Singh R, Elkind MSV, Lloyd-Jones DM, et al. Novel Prediction Equations for Absolute Risk Assessment of Total

Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. *Circulation*. 2023;148(24):1982–2004.

- King SJ, Furst A, Fan J, Chen TP, Maron DJ, Heidenreich P, Nallamshetty S, Kalwani NM, Ward JH, Lozama A, Rodriguez F, Sandhu AT. Comparison of the Pooled Cohort and the PREVENT Cardiovascular Disease Risk Equations in the Veterans Health Administration. *Circulation*. 2025;152(16):1183–1185.
- Additional references provided within slide presentation.

DAY 3 (Original Recording Date: Friday, June 5, 2026)

Focus on Dyslipidemia

Michael Blaha, MD - What's New in the New ACC/AHA Dyslipidemia Guidelines?

- Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, Blankstein R, Brewer LC, Cho L, de Ferranti SD, Gianos E, Gluckman TJ, Gradney KF, Isiadinso I, Lloyd-Jones DM, Marrs JC, Martin SS, McLain KH, Mehta LS, Mora S, Mulugeta WM, Natarajan P, Navar AM, Orringer CE, Polonsky TS, Reynolds HR, Saseen JJ, Shapiro MD, Soffer DE, Tynes SA, Villavaso CD, Virani SS, Wilkins JT. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2026 Mar 13:S0735-1097(25)10254-4. doi: 10.1016/j.jacc.2025.11.016. Epub ahead of print. PMID: 41824590.

Ramzi Dudum - Applying the New ACC/AHA Cholesterol Guidelines in Practice

- Otto CM, et al. <https://doi.org/10.1161/CIR.0000000000001383>
- Blumenthal RS, et al. <https://doi.org/10.1161/CIR.0000000000001423>
- Peng AW, Dudum R, et al. *J Am Coll Cardiol*. 2023;81(12):1192-1202.
- Blaha MJ, et al. *J Cardiovasc Comput Tomogr*. 2016 Nov 11;11(1):54–61
- Additional references provided within slide presentation.

Michael Blaha, MD - What's on the HORIZON with Lp(a): Comparing the Nearly Completed Lp(a) Trials

- Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, Leitersdorf E, Lincoff AM, Lesogor A, Manning B, Kozlovski P, Cao H, Wang J, Nissen SE. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). *Am Heart J*. 2025 Sep;287:1-9. doi: 10.1016/j.ahj.2025.03.019. Epub 2025 Apr 2. PMID: 40185318.
- Razavi AC, Blaha MJ, Sperling LS, Whelton SP. Lp(a) and Inflammation in Cardiovascular Disease: On the Horizon for Risk Assessment and Future Therapies. *J Am Coll Cardiol*. 2025 Nov 25;86(21):2014-2016. doi: 10.1016/j.jacc.2025.10.013. PMID: 41260755.
- Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. *Annu Rev Pharmacol Toxicol*. 2024 Jan 23;64:135-157. doi: 10.1146/annurev-pharmtox-031023-100609. Epub 2023 Jul 28. PMID: 37506332.
- Additional references provided within slide presentation.

Ramzi Dudum - Making Sense of Non-Statin Lipid-Lowering Therapies: The When and Why to Use Them

- Blumenthal RS, et al. <https://doi.org/10.1161/CIR.0000000000001423>
- <https://www.uptodate.com/contents/search?search=statin%20comparison%20chart>
- Cannon CP, et al. DOI: 10.1056/NEJMoa1410489
- Sabatine MS, et al. DOI: 10.1056/NEJMoa1615664
- Schwartz GG., et al. DOI: 10.1056/NEJMoa1801174
- Bohula EA, et al. DOI: 10.1056/NEJMoa2514428
- Additional references provided within slide presentation.

Drs. Blaha & Dudum - Cases in Lipids

- References provided within slide presentation.
-